<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC4247767/results/search/disease/results.xml">
  <result pre="2014-9-15(C) , This article is published under license to BioMed" exact="Central" post="Ltd. This is an Open Access article distributed under"/>
  <result pre="era of antiviral drug therapy, combining multiple drugs is a" exact="primary" post="approach for improving antiviral effects, reducing the doses of"/>
  <result pre="the combined drugs and their target viruses. Mathematical models of" exact="viral infection" post="dynamics provide an ideal tool for this purpose. Additionally,"/>
  <result pre="combined drugs and their target viruses. Mathematical models of viral" exact="infection" post="dynamics provide an ideal tool for this purpose. Additionally,"/>
  <result pre="[21, 22]. These studies have elucidated the key steps of" exact="viral" post="replication cycles and viral infection dynamics, such as the"/>
  <result pre="have elucidated the key steps of viral replication cycles and" exact="viral infection" post="dynamics, such as the half-life of viruses and how"/>
  <result pre="elucidated the key steps of viral replication cycles and viral" exact="infection" post="dynamics, such as the half-life of viruses and how"/>
  <result pre="how viruses replicate in cells (reviewed in [23–27]). Although mathematical" exact="viral" post="models could also search for drug combinations that improve"/>
  <result pre="and prevent the emergence of drug-resistant viruses, this potential of" exact="viral" post="modeling has yet to be properly explored. Multi-drug administration"/>
  <result pre="experience severe side effects such as lipodystrophy, hepatotoxicity, renal dysfunction," exact="peripheral neuropathy" post="and cardiovascular diseases (reviewed in [28]). By optimizing drug"/>
  <result pre="severe side effects such as lipodystrophy, hepatotoxicity, renal dysfunction, peripheral" exact="neuropathy" post="and cardiovascular diseases (reviewed in [28]). By optimizing drug"/>
  <result pre="effects such as lipodystrophy, hepatotoxicity, renal dysfunction, peripheral neuropathy and" exact="cardiovascular" post="diseases (reviewed in [28]). By optimizing drug combinations, we"/>
  <result pre="is crucial to fundamental antiviral research. Here we discuss two" exact="primary" post="concepts of drug combination theory: Loewe additivity and Bliss"/>
  <result pre="Loewe additivity and Bliss independence. We apply these models to" exact="viral" post="replication in a host cell, and discuss their utility"/>
  <result pre="cell, and discuss their utility for understanding two-drug interactions and" exact="viral" post="dynamics. Finally, we discuss how drug combination theory might"/>
  <result pre="we discuss how drug combination theory might be applied to" exact="cancer" post="chemotherapies and antiviral therapies. Combining mathematical models of viral"/>
  <result pre="to cancer chemotherapies and antiviral therapies. Combining mathematical models of" exact="viral" post="replication with drug combination theory, we can establish an"/>
  <result pre="combination theory: Loewe additivity Loewe additivity is regarded as a" exact="primary" post="criterion for evaluating drug combination effects [29]. To conceptualize"/>
  <result pre="usefulness of combining the Loewe additivity with mathematical modeling of" exact="hepatitis" post="C virus (HCV) replication. The aim is to optimize"/>
  <result pre="acting antiviral (DAA) drugs that target viral-specific proteins such as" exact="viral" post="proteases, as adjuncts to conventional anti-HCV drugs. To understand"/>
  <result pre="could predict the optimal drug combination that both reduces the" exact="total" post="dose of each drug and enhances their anti-HCV effects."/>
  <result pre="optimal drug combination from the mechanism of drug effects on" exact="viral" post="replication. A) Conceptual diagram showing the effects of two"/>
  <result pre="inhibits virus release, and drug B inhibits the production of" exact="viral" post="polymerase. To calculate the effect of co-administered A and"/>
  <result pre="A and B on HCV production, the dynamics of each" exact="viral" post="component during the replication are expressed by differential equations"/>
  <result pre="of both drugs decreases the parameters, a production rate of" exact="viral" post="proteins and a releasing rate of virions. B) Estimation"/>
  <result pre="the effects of the combined drugs obtained by modeling the" exact="viral" post="dynamics and the additive effects calculated by Loewe additivity."/>
  <result pre="assumes that each drug independently targets a different stage of" exact="viral" post="replication via a different mechanism, with no interaction between"/>
  <result pre="by drug A will be intercepted by drug B. The" exact="total" post="probability of missed targets is obtained by multiplying the"/>
  <result pre="HIV replication in cells by two main mechanisms: (1) inhibiting" exact="viral" post="reverse transcriptase and (2) mutating cytidine (C) to uracil"/>
  <result pre="transcriptase and (2) mutating cytidine (C) to uracil (U) in" exact="viral" post="DNA by cytidine deaminase activity (Figure 2A). Although the"/>
  <result pre="can use Bliss independence to model the unaffected fractions of" exact="viral" post="infectivity of wild-type (WT) and mutant APOBEC3G, denoted fWT"/>
  <result pre="and fCI respectively, in terms of the unaffected fractions of" exact="viral" post="infectivity by reverse transcription inhibition and C-to-U mutation, fRT"/>
  <result pre="replication. B) Quantification of antiviral effects of mutant APOBEC3G on" exact="HIV infection." post="HIV production reduces with increasing expression of APOBEC3G (dots:"/>
  <result pre="drug targets are decided. For example, using computational modeling of" exact="cancer" post="signaling networks and animal experiments, Kirouac et al.[46] identified"/>
  <result pre="the optimal inhibitor combination for suppressing the growth of ERBB2-amplified" exact="breast cancer." post="They adopted Bliss independence as a synergy criterion. Supplementing"/>
  <result pre="a biological system. The above research potentially benefits not only" exact="cancer" post="chemotherapy, but also antiviral therapy development. For instance, Owens"/>
  <result pre="3). Figure 3 Concept of integrating drug combination theory and" exact="viral" post="dynamics. The effect of a drug combination calculated by"/>
  <result pre="effect of a drug combination calculated by mathematical modeling of" exact="viral" post="dynamics could be assessed by the Loewe additivity and"/>
  <result pre="and discussed how combining these theories with mathematical modeling of" exact="viral" post="dynamics might assist antiviral drug therapy. In addition, we"/>
  <result pre="modeling is a new approach with great potential for showing" exact="viral" post="responses to drug combinations, and accelerating novel antiviral drug"/>
  <result pre="and CD4 lymphocytes in HIV-1 infectionNature199537312312610.1038/373123a07816094 2.WeiXGhoshSKTaylorMEJohnsonVAEminiEADeutschPLifsonJDBonhoefferSNowakMAHahnBHViral dynamics in human" exact="immunodeficiency" post="virus type 1 infectionNature199537311712210.1038/373117a07529365 3.NowakMABonhoefferSLovedayCBalfePSempleMKayeSTenant-FlowersMTedderRHIV results in the frame."/>
  <result pre="lymphocytes in HIV-1 infectionNature199537312312610.1038/373123a07816094 2.WeiXGhoshSKTaylorMEJohnsonVAEminiEADeutschPLifsonJDBonhoefferSNowakMAHahnBHViral dynamics in human immunodeficiency virus" exact="type 1" post="infectionNature199537311712210.1038/373117a07529365 3.NowakMABonhoefferSLovedayCBalfePSempleMKayeSTenant-FlowersMTedderRHIV results in the frame. Results confirmedNature199537519310.1038/375193a07746311 4.CoffinJMHIV"/>
  <result pre="dynamics in vivo: virion clearance rate, infected cell life-span, and" exact="viral" post="generation timeScience19962711582158610.1126/science.271.5255.15828599114 6.WeinLMZeniosSANowakMADynamic multidrug therapies for HIV: a control"/>
  <result pre="WolfFPerelsonASMittlerJRate of HIV-1 decline following antiretroviral therapy is related to" exact="viral" post="load at baseline and drug regimenAIDS1998121483149010.1097/00002030-199812000-000109727569 9.WeinLMD’AmatoRMPerelsonASMathematical analysis of"/>
  <result pre="antiretroviral therapy aimed at HIV-1 eradication or maintenance of low" exact="viral" post="loadsJ Theor Biol1998192819810.1006/jtbi.1997.06229628841 10.Di MascioMMarkowitzMLouieMHoganCHurleyAChungCHoDDPerelsonASViral blip dynamics during highly"/>
  <result pre="dynamics of HIV-1 depend on the inhibited stages of the" exact="viral" post="life cycleProc Natl Acad Sci U S A20081054832483710.1073/pnas.071137210518362342 12.ShenLRabiSASedaghatARShanLLaiJXingSSilicianoRFA"/>
  <result pre="dynamics in vivo: effect of ribavirin and interferon alfa on" exact="viral" post="turnoverHepatology19982824525210.1002/hep.5102801329657119 15.NeumannAULamNPDahariHGretchDRWileyTELaydenTJPerelsonASHepatitis C viral dynamics in vivo and the"/>
  <result pre="of ribavirin and interferon alfa on viral turnoverHepatology19982824525210.1002/hep.5102801329657119 15.NeumannAULamNPDahariHGretchDRWileyTELaydenTJPerelsonASHepatitis C" exact="viral" post="dynamics in vivo and the antiviral efficacy of interferon-alpha"/>
  <result pre="interferon-alpha therapyScience199828210310710.1126/science.282.5386.1039756471 16.DixitNMLayden-AlmerJELaydenTJPerelsonASModelling how ribavirin improves interferon response rates in" exact="hepatitis" post="C virus infectionNature200443292292410.1038/nature0315315602565 17.DahariHRibeiroRMPerelsonASTriphasic decline of hepatitis C virus"/>
  <result pre="response rates in hepatitis C virus infectionNature200443292292410.1038/nature0315315602565 17.DahariHRibeiroRMPerelsonASTriphasic decline of" exact="hepatitis" post="C virus RNA during antiviral therapyHepatology200746162110.1002/hep.2165717596864 18.DahariHSainzBPerelsonASUprichardSLModeling subgenomic hepatitis"/>
  <result pre="of hepatitis C virus RNA during antiviral therapyHepatology200746162110.1002/hep.2165717596864 18.DahariHSainzBPerelsonASUprichardSLModeling subgenomic" exact="hepatitis" post="C virus RNA kinetics during treatment with alpha interferonJ"/>
  <result pre="RNA kinetics during treatment with alpha interferonJ Virol2009836383639010.1128/JVI.02612-0819369346 19.LewinSRRibeiroRMWaltersTLauGKBowdenSLocarniniSPerelsonASAnalysis of" exact="hepatitis" post="B viral load decline under potent therapy: complex decay"/>
  <result pre="during treatment with alpha interferonJ Virol2009836383639010.1128/JVI.02612-0819369346 19.LewinSRRibeiroRMWaltersTLauGKBowdenSLocarniniSPerelsonASAnalysis of hepatitis B" exact="viral" post="load decline under potent therapy: complex decay profiles observedHepatology2001341012102010.1053/jhep.2001.2850911679973"/>
  <result pre="therapy: complex decay profiles observedHepatology2001341012102010.1053/jhep.2001.2850911679973 20.DahariHShudoERibeiroRMPerelsonASModeling complex decay profiles of" exact="hepatitis" post="B virus during antiviral therapyHepatology200949323810.1002/hep.2258619065674 21.BeaucheminCAAMcSharryJJDrusanoGLNguyenJTWentGTRibeiroRMPerelsonASModeling amantadine treatment of"/>
  <result pre="Dynamics: Mathematical Principles of Immunology and Virology2001USAOxford University Press256 24.PerelsonASModelling" exact="viral" post="and immune system dynamicsNat Rev Immunol20022283610.1038/nri70011905835 25.RongLPerelsonASModeling HIV persistence,"/>
  <result pre="dynamicsNat Rev Immunol20022283610.1038/nri70011905835 25.RongLPerelsonASModeling HIV persistence, the latent reservoir, and" exact="viral" post="blipsJ Theor Biol200926030833110.1016/j.jtbi.2009.06.01119539630 26.GuedjJRongLDahariHPerelsonASA perspective on modelling hepatitis C"/>
  <result pre="reservoir, and viral blipsJ Theor Biol200926030833110.1016/j.jtbi.2009.06.01119539630 26.GuedjJRongLDahariHPerelsonASA perspective on modelling" exact="hepatitis" post="C virus infectionJ Viral Hepat20101782583310.1111/j.1365-2893.2010.01348.x20723038 27.ChatterjeeAGuedjJPerelsonASMathematical modelling of HCV"/>
  <result pre="Theor Biol200926030833110.1016/j.jtbi.2009.06.01119539630 26.GuedjJRongLDahariHPerelsonASA perspective on modelling hepatitis C virus infectionJ" exact="Viral" post="Hepat20101782583310.1111/j.1365-2893.2010.01348.x20723038 27.ChatterjeeAGuedjJPerelsonASMathematical modelling of HCV infection: what can it"/>
  <result pre="to evaluate interactions between drugsBiochem Pharmacol19965163564410.1016/S0006-2952(95)02230-98615900 37.DahariHRibeiroRMRiceCMPerelsonASMathematical modeling of subgenomic" exact="hepatitis" post="C virus replication in Huh-7 cellsJ Virol20078175076010.1128/JVI.01304-0617035310 38.McLeanAKLucianiFTanakaMMTrade-offs in"/>
  <result pre="Virol20078175076010.1128/JVI.01304-0617035310 38.McLeanAKLucianiFTanakaMMTrade-offs in resource allocation in the intracellular life-cycle of" exact="hepatitis" post="C virusJ Theor Biol201026756557210.1016/j.jtbi.2010.09.03120883700 39.NakabayashiJA compartmentalization model of hepatitis"/>
  <result pre="of hepatitis C virusJ Theor Biol201026756557210.1016/j.jtbi.2010.09.03120883700 39.NakabayashiJA compartmentalization model of" exact="hepatitis" post="C virus replication: an appropriate distribution of HCV RNA"/>
  <result pre="Theor Biol201230011011710.1016/j.jtbi.2012.01.02322286015 40.BinderMSulaimanovNClausznitzerDSchulzeMHüberCMLenzSMSchlöderJPTripplerMBartenschlagerRLohmannVKaderaliLReplication vesicles are load- and choke-points in the" exact="hepatitis" post="C virus lifecyclePLoS Pathog20139e100356110.1371/journal.ppat.100356123990783 41.JonkerDMVisserSAvan der GraafPHVoskuylRADanhofMTowards a mechanism-based"/>
  <result pre="sum of the partsDrug Discov Today200712344210.1016/j.drudis.2006.11.00817198971 46.KirouacDCDuJYLahdenrantaJOverlandRYararDParagasVPaceEMcDonaghCFNielsenUBOnsumMDComputational modeling of ERBB2-amplified" exact="breast cancer" post="identifies combined ErbB2/3 blockade as superior to the combination"/>
  <result pre="of the partsDrug Discov Today200712344210.1016/j.drudis.2006.11.00817198971 46.KirouacDCDuJYLahdenrantaJOverlandRYararDParagasVPaceEMcDonaghCFNielsenUBOnsumMDComputational modeling of ERBB2-amplified breast" exact="cancer" post="identifies combined ErbB2/3 blockade as superior to the combination"/>
  <result pre="Biol200738010.1038/msb410011617332758 49.OwensCMMawhinneyCGrenierJMAltmeyerRLeeMSBorisyAALehárJJohansenLMChemical combinations elucidate pathway interactions and regulation relevant to" exact="Hepatitis" post="C replicationMol Syst Biol2010637510.1038/msb.2010.3220531405 50.GuedjJPerelsonASSecond-phase hepatitis C virus RNA"/>
  <result pre="and regulation relevant to Hepatitis C replicationMol Syst Biol2010637510.1038/msb.2010.3220531405 50.GuedjJPerelsonASSecond-phase" exact="hepatitis" post="C virus RNA decline during telaprevir-based therapy increases with"/>
  <result pre="therapy increases with drug effectiveness: implications for treatment durationHepatology2011531801180810.1002/hep.2427221384401 51.GuedjJNeumannAUUnderstanding" exact="hepatitis" post="C viral dynamics with direct-acting antiviral agents due to"/>
  <result pre="with drug effectiveness: implications for treatment durationHepatology2011531801180810.1002/hep.2427221384401 51.GuedjJNeumannAUUnderstanding hepatitis C" exact="viral" post="dynamics with direct-acting antiviral agents due to the interplay"/>
  <result pre="agents due to the interplay between intracellular replication and cellular" exact="infection" post="dynamicsJ Theor Biol201026733034010.1016/j.jtbi.2010.08.03620831874 52.GuedjJDahariHRongLSansoneNDNettlesRECotlerSJLaydenTJUprichardSLPerelsonASModeling shows that the NS5A inhibitor"/>
  <result pre="modes of action and yields a shorter estimate of the" exact="hepatitis" post="C virus half-lifeProc Natl Acad Sci U S A20131103991399610.1073/pnas.120311011023431163"/>
  <result pre="virus half-lifeProc Natl Acad Sci U S A20131103991399610.1073/pnas.120311011023431163 53.RongLGuedjJDahariHCoffieldDJLeviMSmithPPerelsonASAnalysis of" exact="hepatitis" post="C virus decline during treatment with the protease inhibitor"/>
  <result pre="multiscale modelPLoS Comput Biol20139e100295910.1371/journal.pcbi.100295923516348 54.RongLPerelsonASMathematical analysis of multiscale models for" exact="hepatitis" post="C virus dynamics under therapy with direct-acting antiviral agentsMath"/>
  <result pre="antiviral agentsMath Biosci2013245223010.1016/j.mbs.2013.04.01223684949 55.RongLDahariHRibeiroRMPerelsonASRapid emergence of protease inhibitor resistance in" exact="hepatitis" post="C virusSci Transl Med2010230ra3210.1126/scitranslmed.300054420445200"/>
 </snippets>
</snippetsTree>
